AU-007
- Generic Name
- AU-007
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorMetastatic Cancer
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Aulos Bioscience, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT05267626
- Locations
- 🇺🇸
University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇦🇺Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath